Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

Paul Angulo, Tushar Patel, Roberta A. Jorgensen, Terry M. Therneau, Keith Lindor

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC), but some patients show an incomplete response. Silymarin is a potent antioxidant with immunomodulatory and antifibrotic properties. The aim of this study was to evaluate the safety and assess the efficacy of silymarin in patients with PBC who had shown a suboptimal response to UDCA. Twenty-seven patients with PBC who had been on UDCA (13-15 mg/kg/day) therapy for 7 to 221 months and had shown a persistent elevation of alkaline phosphatase activity at least 2 times the upper limit of normal for more than 6 months were enrolled. Oral silymarin, 140 mg 3 times daily was given for 1 year, and patients continued on the same dosage of UDCA. No significant changes in serum alkaline phosphatase activity (897 ± 84 vs. 876 ± 95, P = .5), total bilirubin (0.9 ± 0.1 vs. 1 ± 0.1, P = .07), aspartate transaminase (AST) (58 ± 5 vs. 56 ± 6, P = .4), albumin (4.0 ± .06 vs. 4.1 ± .06, P = .4), or Mayo risk score (3.82 ± 0.2 vs. 3.88 ± 0.2, P = .4) were noted after 1 year of treatment with combination therapy. Transitory gastrointestinal adverse events occurred in 2 patients. In conclusion, although silymarin was well tolerated, this medication did not provide benefit to patients with PBC responding suboptimally to UDCA. The results of this pilot study would seem to discourage further controlled trials of silymarin in patients with PBC.

Original languageEnglish (US)
Pages (from-to)897-900
Number of pages4
JournalHepatology
Volume32
Issue number5
StatePublished - 2000
Externally publishedYes

Fingerprint

Silymarin
Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Therapeutics
Alkaline Phosphatase
Aspartate Aminotransferases
Bilirubin
Albumins
Antioxidants
Safety

ASJC Scopus subject areas

  • Hepatology

Cite this

Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. / Angulo, Paul; Patel, Tushar; Jorgensen, Roberta A.; Therneau, Terry M.; Lindor, Keith.

In: Hepatology, Vol. 32, No. 5, 2000, p. 897-900.

Research output: Contribution to journalArticle

Angulo, Paul ; Patel, Tushar ; Jorgensen, Roberta A. ; Therneau, Terry M. ; Lindor, Keith. / Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. In: Hepatology. 2000 ; Vol. 32, No. 5. pp. 897-900.
@article{d4e4208f10d34782b3c3356b7d07f917,
title = "Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid",
abstract = "Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC), but some patients show an incomplete response. Silymarin is a potent antioxidant with immunomodulatory and antifibrotic properties. The aim of this study was to evaluate the safety and assess the efficacy of silymarin in patients with PBC who had shown a suboptimal response to UDCA. Twenty-seven patients with PBC who had been on UDCA (13-15 mg/kg/day) therapy for 7 to 221 months and had shown a persistent elevation of alkaline phosphatase activity at least 2 times the upper limit of normal for more than 6 months were enrolled. Oral silymarin, 140 mg 3 times daily was given for 1 year, and patients continued on the same dosage of UDCA. No significant changes in serum alkaline phosphatase activity (897 ± 84 vs. 876 ± 95, P = .5), total bilirubin (0.9 ± 0.1 vs. 1 ± 0.1, P = .07), aspartate transaminase (AST) (58 ± 5 vs. 56 ± 6, P = .4), albumin (4.0 ± .06 vs. 4.1 ± .06, P = .4), or Mayo risk score (3.82 ± 0.2 vs. 3.88 ± 0.2, P = .4) were noted after 1 year of treatment with combination therapy. Transitory gastrointestinal adverse events occurred in 2 patients. In conclusion, although silymarin was well tolerated, this medication did not provide benefit to patients with PBC responding suboptimally to UDCA. The results of this pilot study would seem to discourage further controlled trials of silymarin in patients with PBC.",
author = "Paul Angulo and Tushar Patel and Jorgensen, {Roberta A.} and Therneau, {Terry M.} and Keith Lindor",
year = "2000",
language = "English (US)",
volume = "32",
pages = "897--900",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

AU - Angulo, Paul

AU - Patel, Tushar

AU - Jorgensen, Roberta A.

AU - Therneau, Terry M.

AU - Lindor, Keith

PY - 2000

Y1 - 2000

N2 - Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC), but some patients show an incomplete response. Silymarin is a potent antioxidant with immunomodulatory and antifibrotic properties. The aim of this study was to evaluate the safety and assess the efficacy of silymarin in patients with PBC who had shown a suboptimal response to UDCA. Twenty-seven patients with PBC who had been on UDCA (13-15 mg/kg/day) therapy for 7 to 221 months and had shown a persistent elevation of alkaline phosphatase activity at least 2 times the upper limit of normal for more than 6 months were enrolled. Oral silymarin, 140 mg 3 times daily was given for 1 year, and patients continued on the same dosage of UDCA. No significant changes in serum alkaline phosphatase activity (897 ± 84 vs. 876 ± 95, P = .5), total bilirubin (0.9 ± 0.1 vs. 1 ± 0.1, P = .07), aspartate transaminase (AST) (58 ± 5 vs. 56 ± 6, P = .4), albumin (4.0 ± .06 vs. 4.1 ± .06, P = .4), or Mayo risk score (3.82 ± 0.2 vs. 3.88 ± 0.2, P = .4) were noted after 1 year of treatment with combination therapy. Transitory gastrointestinal adverse events occurred in 2 patients. In conclusion, although silymarin was well tolerated, this medication did not provide benefit to patients with PBC responding suboptimally to UDCA. The results of this pilot study would seem to discourage further controlled trials of silymarin in patients with PBC.

AB - Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC), but some patients show an incomplete response. Silymarin is a potent antioxidant with immunomodulatory and antifibrotic properties. The aim of this study was to evaluate the safety and assess the efficacy of silymarin in patients with PBC who had shown a suboptimal response to UDCA. Twenty-seven patients with PBC who had been on UDCA (13-15 mg/kg/day) therapy for 7 to 221 months and had shown a persistent elevation of alkaline phosphatase activity at least 2 times the upper limit of normal for more than 6 months were enrolled. Oral silymarin, 140 mg 3 times daily was given for 1 year, and patients continued on the same dosage of UDCA. No significant changes in serum alkaline phosphatase activity (897 ± 84 vs. 876 ± 95, P = .5), total bilirubin (0.9 ± 0.1 vs. 1 ± 0.1, P = .07), aspartate transaminase (AST) (58 ± 5 vs. 56 ± 6, P = .4), albumin (4.0 ± .06 vs. 4.1 ± .06, P = .4), or Mayo risk score (3.82 ± 0.2 vs. 3.88 ± 0.2, P = .4) were noted after 1 year of treatment with combination therapy. Transitory gastrointestinal adverse events occurred in 2 patients. In conclusion, although silymarin was well tolerated, this medication did not provide benefit to patients with PBC responding suboptimally to UDCA. The results of this pilot study would seem to discourage further controlled trials of silymarin in patients with PBC.

UR - http://www.scopus.com/inward/record.url?scp=0033754697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033754697&partnerID=8YFLogxK

M3 - Article

C2 - 11050036

AN - SCOPUS:0033754697

VL - 32

SP - 897

EP - 900

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -